MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Abstract Text:

Mahesha Vankalakunti,Rakesh Kumar Vasishta,Bishan Das Radotra,Virender Kumar Khosla,Mahesha Vankalakunti,Rakesh Kumar Vasishta,Bishan Das Radotra,Virender Kumar Khosla,

Histological analysis has limited value to predict biological behavior of meningiomas. We investigated the utility of cell proliferative indicator in the evaluation of histologically benign meningiomas. We selected 25 benign non-recurrent meningiomas, 15 benign recurrent meningiomas after complete surgical resection, 30 atypical meningiomas, and 15 anaplastic meningiomas out of 384 cases studied. MIB-1 Labeling Index was evaluated by two methods: Highest Labeling Index (HLI) and Random Labeling Index (RLI). There was no dependable histological parameter to predict recurrence among benign-looking meningiomas. HLI had significant difference when compared with RLI in all categories. The mean MIB-1 HLI values +/- SD were 3.47 +/- 2.0% for benign meningiomas, 5.08 +/- 4.0% for atypical meningiomas and 11.66 +/- 7.06% for anaplastic meningiomas. In comparison, the mean MIB-1 HLI of benign non-recurrent meningiomas were 2.66 +/- 1.7% and with recurrence were 4.21 +/- 2.78% (P = 0.0339). Using receiver operating characteristic, it was seen that neoplasm recurred with the MIB-1 HLI of > 2.6 having the sensitivity of 64.6% and specificity of 68% among benign (grade I) meningiomas. MIB-1 positive tumor cells were maximally aggregated at the periphery of excised specimen. MIB-1 HLI, integrated with standard histopathology can provide better information about the disease biological nature in benign meningiomas.

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Publishing Authors By Initials

M Vankalakunti,RK Vasishta,B Das Radotra,VK Khosla,M Vankalakunti,RK Vasishta,B Das Radotra,VK Khosla,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Neuropathology : official journal of the Japanese

VOLUME: 27

Page Numbers: 407-12

Journal Abbreviation:

ISSN: 0919-6544

DAY: 16

MONTH: Oct

YEAR: 2007

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9606526

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.

AFFILIATION: Department of Histopathology, Post Graduate Institute of Medical Education & Research, Chandigarh, India.

Country: Australia

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Neuropathology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas Related Publications

• A Cretaceous hoofed mammal from India.
• A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men.
• A report of two 'traumatic encephaloceles'; an unrecognized entity.
• A scaleable manufacturing process for pro-EP-B2, a cysteine protease from barley indicated for celiac sprue.
• Assessment of gene regulation by bone morphogenetic protein 2 in human marrow stromal cells using gene array technology.
• Bioassay-guided evolution of glycosylated macrolide antibiotics in Escherichia coli.
• Characterization of circulating osteoblast lineage cells in humans.
• Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue.
• Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women.
• DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.
• Does reduced skeletal loading account for age-related bone loss?
• Effects of loss of classical estrogen response element signaling on bone in male mice.
• Enhancement of dietary protein digestion by conjugated bile acids.
• High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
• High-trauma fractures and bone mineral density.
• Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
• Long-term fracture risk among women with proven endometriosis.
• MIB-1 immunolabeling: a valuable marker in prediction of benign recurring meningiomas.
• Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines.
• Production of ansamycin polyketide precursors in Escherichia coli.
• Solution structure and proposed domain domain recognition interface of an acyl carrier protein domain from a modular polyketide synthase.
• Structural determinants of vertebral fracture risk.
• Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
• Structure-activity relationships of semisynthetic mumbaistatin analogs.
• Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2.
• Structure-based dissociation of a type I polyketide synthase module.
• Substrate tolerance of module 6 of the epothilone synthetase.
• Synthesis and biological activity of novel pyranopyrones derived from engineered aromatic polyketides.
• The skeletal response to estrogen is impaired in female but not in male steroid receptor coactivator (SRC)-1 knock out mice.
• Transglutaminase 2 undergoes a large conformational change upon activation.